Core Viewpoint - Analysts expect General Mills to report quarterly earnings of $0.71 per share, reflecting a year-over-year decline of 29.7%, with revenues projected at $4.6 billion, down 2.4% from the previous year [1] Earnings Estimates - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding stocks, with empirical research showing a strong correlation between earnings estimate trends and short-term stock performance [2] Key Metrics Forecast - Analysts estimate 'Net Sales- North America Foodservice' at $593.35 million, indicating a year-over-year change of +0.7% [4] - 'Net Sales- International' is expected to reach $671.56 million, reflecting a +0.6% change from the year-ago quarter [4] - 'Net Sales- North America Pet' is projected at $646.14 million, showing a year-over-year increase of +7.3% [4] - 'Net Sales- North America Retail' is anticipated to be $2.71 billion, indicating a -5% change from the prior-year quarter [5] Operating Profit Estimates - 'Operating Profit- North America Retail' is expected to be $492.98 million, down from $670.10 million year-over-year [5] - 'Operating Profit- International' is projected at $32.83 million, compared to $22.40 million from the previous year [6] - 'Operating Profit- North America Pet' is estimated at $124.25 million, down from $143.90 million year-over-year [6] - 'Operating Profit- North America Foodservice' is expected to be $78.51 million, slightly down from $79.20 million year-ago [6] Stock Performance - Over the past month, General Mills shares have returned -0.8%, while the Zacks S&P 500 composite has changed by +0.6% [7] - General Mills currently holds a Zacks Rank 4 (Sell), indicating potential underperformance compared to the overall market in the near future [7]

Shares of Synaptics (SYNA) have gained 7.3% over the past four weeks to close the last trading session at $62.48, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $87.86 indicates a potential upside of 40.6%.The mean estimate comprises seven short-term price targets with a standard deviation of $11.85. While the lowest estimate of $80 indicates a 28% increase from the current pri ...

Group 1: Company Performance - United Natural Foods (UNFI) shares increased by 7.6% to close at $30.57, with notable trading volume compared to typical sessions, and a total gain of 17.3% over the past four weeks [1][2] - The stock's rise is driven by optimism regarding its wholesale segment, new business from existing and newly acquired customers, and the impact of inflation, alongside a focus on lean management and operational efficiency [2] - The company is expected to report quarterly earnings of $0.23 per share, reflecting a year-over-year increase of 130%, with revenues projected at $7.82 billion, up 4.2% from the previous year [3] Group 2: Earnings Estimates and Market Position - The consensus EPS estimate for UNFI has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] - UNFI currently holds a Zacks Rank of 3 (Hold), while another company in the same industry, Campbell's (CPB), has a Zacks Rank of 4 (Sell) and reported a 1.9% increase in its last trading session [4][5] - Campbell's EPS estimate for the upcoming report is $0.65, which is a decrease of 13.3% from the previous year [5]

Financial Performance - Grindr Inc. reported quarterly earnings of $0.09 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.03 per share a year ago [1] - The company posted revenues of $93.94 million for the quarter ended March 2025, which was 1.01% below the Zacks Consensus Estimate, compared to $75.35 million in the same quarter last year [2] - Over the last four quarters, Grindr has surpassed consensus EPS estimates only once, while it has topped consensus revenue estimates three times [2][1] Stock Performance - Grindr Inc. shares have increased approximately 34.7% since the beginning of the year, contrasting with a decline of 4.3% in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $103.1 million, and for the current fiscal year, it is $0.40 on revenues of $430.3 million [7] - The outlook for the Internet - Software industry, where Grindr operates, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Core Viewpoint - Progyny reported quarterly earnings of $0.48 per share, exceeding the Zacks Consensus Estimate of $0.45 per share, and showing an increase from $0.39 per share a year ago, indicating a positive earnings surprise of 6.67% [1] - The company also posted revenues of $324.04 million for the quarter, surpassing the Zacks Consensus Estimate by 6.60% and up from $278.08 million year-over-year [2] Financial Performance - Over the last four quarters, Progyny has consistently surpassed consensus EPS estimates, achieving this four times [2] - The company has also topped consensus revenue estimates two times in the same period [2] - Progyny shares have increased by approximately 35.8% since the beginning of the year, contrasting with a -4.3% decline in the S&P 500 [3] Future Outlook - The sustainability of the stock's price movement will largely depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - Current consensus EPS estimate for the upcoming quarter is $0.42 on revenues of $306.87 million, and for the current fiscal year, it is $1.62 on revenues of $1.21 billion [7] Industry Context - The Medical Services industry, to which Progyny belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Progyny's stock performance [5]

Company Performance - Avidity Biosciences reported a quarterly loss of $0.90 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.88, and compared to a loss of $0.79 per share a year ago, indicating a negative earnings surprise of -2.27% [1] - The company posted revenues of $1.57 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 46.68%, and down from $3.54 million in the same quarter last year [2] - Over the last four quarters, Avidity has surpassed consensus EPS estimates three times, but has only topped consensus revenue estimates once [2] Market Comparison - Avidity Biosciences shares have declined approximately 10% since the beginning of the year, while the S&P 500 has seen a decline of -4.3% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.86 on revenues of $2.1 million, and for the current fiscal year, it is -$3.90 on revenues of $9.25 million [7] - The estimate revisions trend for Avidity Biosciences is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Avidity belongs, is currently in the top 33% of over 250 Zacks industries, indicating a positive outlook for stocks within this sector [8]

Company Performance - NetScout Systems reported quarterly earnings of $0.52 per share, matching the Zacks Consensus Estimate, but down from $0.55 per share a year ago [1] - The company posted revenues of $204.99 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 3.71% and slightly up from $203.44 million year-over-year [2] - Over the last four quarters, NetScout has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Outlook - The immediate price movement of NetScout's stock will largely depend on management's commentary during the earnings call [3] - NetScout shares have declined approximately 2.1% since the beginning of the year, while the S&P 500 has decreased by 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.26 on revenues of $182.06 million, and for the current fiscal year, it is $2.33 on revenues of $835.92 million [7] Industry Context - The Computer - Networking industry, to which NetScout belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests that the performance of stocks can be significantly influenced by the overall outlook of their respective industries [8]

Airgain (AIRG) came out with a quarterly loss of $0.11 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this antenna products developer would post earnings of $0.03 per share when it actually produced break-even earnings, delivering a surprise of -100%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Airgain, which belongs to ...

California Resources Corporation (CRC) came out with quarterly earnings of $1.07 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recurring items. While California Resources has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address ...

Core Viewpoint - Ardelyx reported a quarterly loss of $0.17 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, marking a 70% earnings surprise [1] - The company posted revenues of $74.11 million for the quarter, missing the Zacks Consensus Estimate by 8.14%, but showing growth from $46.02 million a year ago [2] Financial Performance - Over the last four quarters, Ardelyx has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $87.7 million, and for the current fiscal year, it is -$0.20 on revenues of $364.02 million [7] Market Position - Ardelyx shares have increased by approximately 8.6% since the beginning of the year, contrasting with a -5.3% decline in the S&P 500 [3] - The Zacks Industry Rank for Medical - Drugs is in the top 23% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] Future Outlook - The sustainability of Ardelyx's stock price movement will depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The estimate revisions trend for Ardelyx is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market [6]